Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Earnings
NGM Biopharmaceuticals reports Q2 EPS (38c), consensus (31c) » 16:10
08/12/20
08/12
16:10
08/12/20
16:10
NGM

NGM Biopharmaceuticals

$18.55 /

-0.34 (-1.80%)

Reports Q2 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
NGM NGM Biopharmaceuticals
$18.55 /

-0.34 (-1.80%)

NGM NGM Biopharmaceuticals
$18.55 /

-0.34 (-1.80%)

07/30/20 Piper Sandler
NGM Biopharmaceuticals initiated with an Overweight at Piper Sandler
07/07/20 Chardan
NGM Biopharmaceuticals initiated with a Buy at Chardan
06/04/20 BMO Capital
NGM Biopharmaceuticals initiated with an Outperform at BMO Capital
05/06/20 Stifel
Stifel says semaglutide data a 'slight positive' for NGM Biopharmaceuticals
NGM NGM Biopharmaceuticals
$18.55 /

-0.34 (-1.80%)

NGM NGM Biopharmaceuticals
$18.55 /

-0.34 (-1.80%)

NGM NGM Biopharmaceuticals
$18.55 /

-0.34 (-1.80%)

Hot Stocks
FDA grants accelerated approval to NS Pharma's DMD treatment Viltepso » 14:20
08/12/20
08/12
14:20
08/12/20
14:20
SRPT

Sarepta

$158.21 /

+0.12 (+0.08%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration granted accelerated approval to Viltepso injection for the treatment of Duchenne muscular dystrophy, or DMD, in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. The FDA is granting the approval to NS Pharma. "This is the second FDA-approved targeted treatment for patients with this type of mutation. Approximately 8% of patients with DMD have a mutation that is amenable to exon 53 skipping," the FDA stated. Previously, on December 12, 2019, Sarepta Therapeutics announced that the U.S. Food and Drug Administration had approved Vyondys 53, an antisense oligonucleotide from Sarepta's phosphorodiamidate morpholino oligomer platform, indicated for the treatment of Duchenne muscular dystrophy in patients with a confirmed mutation amenable to exon 53 skipping.

ShowHide Related Items >><<
SRPT Sarepta
$158.21 /

+0.12 (+0.08%)

SRPT Sarepta
$158.21 /

+0.12 (+0.08%)

08/04/20 Piper Sandler
Sarepta price target lowered to $200 from $206 at Piper Sandler
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
SRPT Sarepta
$158.21 /

+0.12 (+0.08%)

SRPT Sarepta
$158.21 /

+0.12 (+0.08%)

SRPT Sarepta
$158.21 /

+0.12 (+0.08%)

Hot Stocks
Eloxx Pharmaceuticals resumes enrollment in Phase 2 CF trial of ELX-02 » 07:34
08/12/20
08/12
07:34
08/12/20
07:34
ELOX

Eloxx Pharmaceuticals

$3.11 /

+0.07 (+2.30%)

Eloxx Pharmaceuticals…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ELOX Eloxx Pharmaceuticals
$3.11 /

+0.07 (+2.30%)

ELOX Eloxx Pharmaceuticals
$3.11 /

+0.07 (+2.30%)

06/17/20 Piper Sandler
Piper Sandler backs Overweight on Eloxx as cystic fibrosis trials resume
06/11/20
Fly Intel: Top five analyst downgrades
06/11/20 Citi
Citi downgrades Eloxx Pharmaceuticals on cystic fibrosis trial pause
06/10/20 Citi
Eloxx Pharmaceuticals downgraded to Neutral from Buy at Citi
ELOX Eloxx Pharmaceuticals
$3.11 /

+0.07 (+2.30%)

ELOX Eloxx Pharmaceuticals
$3.11 /

+0.07 (+2.30%)

Conference/Events
Sarepta management to meet virtually with Cantor Fitzgerald » 04:55
08/12/20
08/12
04:55
08/12/20
04:55
SRPT

Sarepta

$158.09 /

-1.14 (-0.72%)

Virtual Meetings to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SRPT Sarepta
$158.09 /

-1.14 (-0.72%)

SRPT Sarepta
$158.09 /

-1.14 (-0.72%)

08/04/20 Piper Sandler
Sarepta price target lowered to $200 from $206 at Piper Sandler
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
SRPT Sarepta
$158.09 /

-1.14 (-0.72%)

SRPT Sarepta
$158.09 /

-1.14 (-0.72%)

SRPT Sarepta
$158.09 /

-1.14 (-0.72%)

Yesterday
Hot Stocks
Sarepta, University of Florida collaborate for rare genetic disease therapies » 08:51
08/11/20
08/11
08:51
08/11/20
08:51
SRPT

Sarepta

$159.23 /

+0.34 (+0.21%)

Sarepta Therapeutics and…

Sarepta Therapeutics and the University of Florida announced a strategic collaboration to enable cutting-edge research for novel genetic medicines. Through the agreement, Sarepta will fund multiple research programs at the University, and will have an exclusive option to further develop any new therapeutic compounds that result from the funded research programs. Through the collaboration, currently unique to UF, funding has been allocated for four innovative projects. These projects include exploratory research in novel gene therapy vectors, next-generation capsids and gene editing technologies as well as work in new therapeutic areas in degenerative genetic diseases. The goal is to foster early relationships with experts and accelerate the scientific advancements that lead to the development of transformational precision genetic medicines for patients in need.

ShowHide Related Items >><<
SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

08/04/20 Piper Sandler
Sarepta price target lowered to $200 from $206 at Piper Sandler
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

Recommendations
PTC Therapeutics price target lowered to $75 from $85 at Cantor Fitzgerald » 07:11
08/11/20
08/11
07:11
08/11/20
07:11
PTCT

PTC Therapeutics

$47.98 /

+0.23 (+0.48%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Alethia Young lowered the firm's price target on PTC Therapeutics (PTCT) to $75 from $85 and keeps an Overweight rating on the shares after adjusting for the quarter and the Royalty Pharma (RPRX) deal. While PTC has sold 43% of its royalties to Royalty Pharma, Young still thinks there is upside to the future risdiplam royalty stream relative to the Street expectations.

ShowHide Related Items >><<
PTCT PTC Therapeutics
$47.98 /

+0.23 (+0.48%)

PTCT PTC Therapeutics
$47.98 /

+0.23 (+0.48%)

07/20/20 Credit Suisse
Credit Suisse downgrades PTC Therapeutics after risdiplam royalty deal
07/20/20 Credit Suisse
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
06/09/20 Citi
PTC Therapeutics pipeline not fully appreciated, says Citi
PTCT PTC Therapeutics
$47.98 /

+0.23 (+0.48%)

  • 18
    Sep
PTCT PTC Therapeutics
$47.98 /

+0.23 (+0.48%)

PTCT PTC Therapeutics
$47.98 /

+0.23 (+0.48%)

Conference/Events
Sarepta management to meet virtually with Cantor Fitzgerald » 04:55
08/11/20
08/11
04:55
08/11/20
04:55
SRPT

Sarepta

$159.23 /

+0.34 (+0.21%)

Virtual Meetings to be…

Virtual Meetings to be held on August 11-12 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

08/04/20 Piper Sandler
Sarepta price target lowered to $200 from $206 at Piper Sandler
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

Monday
Syndicate
PTC Therapeutics files automatic mixed securities shelf  16:20
08/10/20
08/10
16:20
08/10/20
16:20
PTCT

PTC Therapeutics

$47.98 /

+0.23 (+0.48%)

 
ShowHide Related Items >><<
PTCT PTC Therapeutics
$47.98 /

+0.23 (+0.48%)

PTCT PTC Therapeutics
$47.98 /

+0.23 (+0.48%)

07/20/20 Credit Suisse
Credit Suisse downgrades PTC Therapeutics after risdiplam royalty deal
07/20/20 Credit Suisse
PTC Therapeutics downgraded to Neutral from Outperform at Credit Suisse
07/20/20 Truist
PTC Therapeutics price target raised to $86 from $75 at SunTrust
06/09/20 Citi
PTC Therapeutics pipeline not fully appreciated, says Citi
PTCT PTC Therapeutics
$47.98 /

+0.23 (+0.48%)

  • 18
    Sep
PTCT PTC Therapeutics
$47.98 /

+0.23 (+0.48%)

PTCT PTC Therapeutics
$47.98 /

+0.23 (+0.48%)

Recommendations
Amarin Perform rating affirmed at Oppenheimer after FDA approves Vascepa generic » 15:18
08/10/20
08/10
15:18
08/10/20
15:18
AMRN

Amarin

$6.96 /

-0.03 (-0.43%)

, RDY

Dr. Reddy's

$62.06 /

+1.75 (+2.90%)

Oppenheimer analyst…

Oppenheimer analyst Leland Gershell reiterated a Perform rating and $7 price target on Amarin (AMRN) after the FDA's Orange Book was updated to reflect the addition of Dr. Reddy's (RDY) generic form of Vascepa. Gershell said that while he has little insight on the prospects that either company will launch at risk while the patent appeal process continues, he believes it is "reasonable" to conclude that the addition of a second generic player will only raise any likelihood of this scenario.

ShowHide Related Items >><<
RDY Dr. Reddy's
$62.06 /

+1.75 (+2.90%)

AMRN Amarin
$6.96 /

-0.03 (-0.43%)

AMRN Amarin
$6.96 /

-0.03 (-0.43%)

06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
RDY Dr. Reddy's
$62.06 /

+1.75 (+2.90%)

07/30/20 Barclays
Dr. Reddy's price target raised to $53 from $45 at Barclays
04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
RDY Dr. Reddy's
$62.06 /

+1.75 (+2.90%)

AMRN Amarin
$6.96 /

-0.03 (-0.43%)

AMRN Amarin
$6.96 /

-0.03 (-0.43%)

RDY Dr. Reddy's
$62.06 /

+1.75 (+2.90%)

AMRN Amarin
$6.96 /

-0.03 (-0.43%)

AMRN Amarin
$6.96 /

-0.03 (-0.43%)

Hot Stocks
Dr. Reddy's receives FDA approval for generic version of Icosapent Ethyl » 14:34
08/10/20
08/10
14:34
08/10/20
14:34
RDY

Dr. Reddy's

$62.07 /

+1.76 (+2.92%)

, AMRN

Amarin

$7.13 /

+0.14 (+2.00%)

Icosapent Ethyl is sold…

Icosapent Ethyl is sold by Amarin (AMRN) under the brand name Vascepa. Amarin has an ongoing appeal versus Hikma and Dr. Reddy's (RDY) related to Vascepa. Reference Link

ShowHide Related Items >><<
RDY Dr. Reddy's
$62.07 /

+1.76 (+2.92%)

AMRN Amarin
$7.13 /

+0.14 (+2.00%)

RDY Dr. Reddy's
$62.07 /

+1.76 (+2.92%)

07/30/20 Barclays
Dr. Reddy's price target raised to $53 from $45 at Barclays
06/17/20 SVB Leerink
Amarin doubling down on appeal after settlement with Apotex, says SVB Leerink
06/17/20 Stifel
Amarin settlement with Apotex an 'incremental positive,' says Stifel
04/21/20 Nomura Instinet
Dr. Reddy's price target raised to INR 4,426 from INR 3,684
AMRN Amarin
$7.13 /

+0.14 (+2.00%)

06/08/20 Jefferies
Jefferies sees growing reasons to believe Amarin may win Vascepa appeal
05/22/20 Roth Capital
Roth Capital says buy Amarin as at-risk generic launch unlikely
RDY Dr. Reddy's
$62.07 /

+1.76 (+2.92%)

AMRN Amarin
$7.13 /

+0.14 (+2.00%)

AMRN Amarin
$7.13 /

+0.14 (+2.00%)

RDY Dr. Reddy's
$62.07 /

+1.76 (+2.92%)

AMRN Amarin
$7.13 /

+0.14 (+2.00%)

AMRN Amarin
$7.13 /

+0.14 (+2.00%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.